Vanguard Group Inc Sells 26,336 Shares of Syndax Pharmaceuticals Inc (SNDX)

Vanguard Group Inc lessened its holdings in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 736,604 shares of the company’s stock after selling 26,336 shares during the period. Vanguard Group Inc owned about 2.97% of Syndax Pharmaceuticals worth $5,951,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SNDX. Claraphi Advisory Network LLC bought a new stake in Syndax Pharmaceuticals during the 3rd quarter worth approximately $129,000. Bank of America Corp DE grew its holdings in Syndax Pharmaceuticals by 1,382.0% during the 2nd quarter. Bank of America Corp DE now owns 28,084 shares of the company’s stock valued at $197,000 after buying an additional 26,189 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Syndax Pharmaceuticals by 72.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 80,372 shares of the company’s stock valued at $564,000 after buying an additional 33,892 shares in the last quarter. Bridgeway Capital Management Inc. grew its holdings in Syndax Pharmaceuticals by 101.6% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 101,800 shares of the company’s stock valued at $823,000 after buying an additional 51,300 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its holdings in Syndax Pharmaceuticals by 79.1% during the 3rd quarter. Panagora Asset Management Inc. now owns 156,513 shares of the company’s stock valued at $1,265,000 after buying an additional 69,130 shares in the last quarter. Hedge funds and other institutional investors own 61.82% of the company’s stock.

SNDX has been the subject of a number of research analyst reports. Robert W. Baird initiated coverage on shares of Syndax Pharmaceuticals in a report on Friday, January 4th. They set an “outperform” rating for the company. B. Riley initiated coverage on shares of Syndax Pharmaceuticals in a report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 target price for the company. Morgan Stanley lowered shares of Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 target price for the company. in a report on Monday, October 29th. ValuEngine lowered shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, November 26th. Finally, HC Wainwright cut their target price on shares of Syndax Pharmaceuticals to $23.00 and set a “buy” rating for the company in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. Syndax Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $16.25.

SNDX traded up $0.01 during trading on Monday, reaching $6.01. The company had a trading volume of 234 shares, compared to its average volume of 126,977. The company has a market cap of $149.04 million, a PE ratio of -2.07 and a beta of 2.38. Syndax Pharmaceuticals Inc has a 52 week low of $3.39 and a 52 week high of $15.20.

COPYRIGHT VIOLATION NOTICE: “Vanguard Group Inc Sells 26,336 Shares of Syndax Pharmaceuticals Inc (SNDX)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.thelincolnianonline.com/2019/02/11/vanguard-group-inc-sells-26336-shares-of-syndax-pharmaceuticals-inc-sndx.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Read More: Average Daily Trade Volume – ADTV

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals Inc (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply